Histidine-enriched lipopeptides with linoleic acid tails delivered functional siRNA into triple-negative breast cancer cells with efficacy matching commercial reagents, and combination with doxorubicin outperformed gene silencing alone.
Comparable to commercial reagentlipopeptides with linoleyl tails matched HiPerFect efficacy for ERK1/2 gene silencing in TNBC cells, with added serum stability
What the researchers found
Cyclic and linear peptides with an Arg-DHis-Arg template and two lipidic moieties achieved high intracellular siRNA delivery. The histidine residues enabled pH-dependent endosomal release: hydrogen bonding between Arg and His side chains was stable at physiological pH but dissociated at the lower pH inside endosomes, triggering cargo release.
Peptides with two linoleyl moieties demonstrated ERK1/2 gene silencing in TNBC cells comparable to the commercial reagent HiPerFect. The peptides were protease-resistant and provided serum stability to siRNA. Combination therapy using ERK1/2-silencing siRNA delivered via gramicidin plus doxorubicin was more effective than siRNA monotherapy for TNBC treatment.
Why it matters
Triple-negative breast cancer is the most aggressive breast cancer subtype with limited targeted treatment options. RNA-based therapies could specifically silence cancer-driving genes, but delivering fragile siRNA molecules into cells has been a major bottleneck. These engineered lipopeptides solve multiple delivery challenges — membrane penetration, endosomal escape, and serum stability — in one designed molecule.
How the study worked
The researchers designed peptide transporters using computational studies and molecular dynamics simulations to optimize the Arg-DHis-Arg template. They synthesized cyclic and linear lipopeptide variants with different lipid modifications (including linoleic acid). They tested siRNA delivery, gene silencing (ERK1/2 knockdown), serum stability, and protease resistance in TNBC cell lines. Combination therapy experiments paired siRNA delivery with doxorubicin.
What this study cannot tell us
All experiments were conducted in cell culture, not in animal models or patients. The comparison was made to a commercial transfection reagent, not to clinically relevant delivery systems. Toxicity profiles in normal cells and in vivo biodistribution were not reported. The scalability of lipopeptide synthesis for clinical use was not addressed.
How to read the evidence
This is a preclinical cell culture study demonstrating proof of concept for a new peptide-based siRNA delivery system. While the design is rational and results are promising, in vivo validation is needed.
When this study was published
Published in 2019, this study contributes to the evolving field of peptide-based RNA delivery. The siRNA therapeutics field has advanced significantly since then, with several approved drugs.
The bigger picture
RNA-based therapeutics are a rapidly growing field following the success of mRNA vaccines and FDA-approved siRNA drugs. Peptide-based delivery systems are attractive because they can be rationally designed, are biodegradable, and can be tuned for specific cell types. This work advances the design principles for pH-responsive peptide carriers that could enable the next generation of targeted RNA therapies for difficult-to-treat cancers.
Questions still open
- Do these lipopeptides show similar siRNA delivery efficiency and tumor reduction in animal models of TNBC?
- Could this delivery platform be adapted for other RNA therapeutics like mRNA or antisense oligonucleotides?
- What is the toxicity profile of these lipopeptides in normal breast tissue and other organs?
Common questions
What is siRNA and why is it important for cancer treatment?
Why is triple-negative breast cancer so hard to treat?
Read the original research
Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells.
ACS applied materials & interfaces, 11(5), 4719-4736
Citation
Biswas, Abhijit; Chakraborty, Kasturee; Dutta, Chiranjit; Mukherjee, Sanchita; Gayen, Paramita; Jan, Somnath; Mallick, Argha Mario; Bhattacharyya, Dhananjay; Sinha Roy, Rituparna. (2019). Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells.. ACS applied materials & interfaces, 11(5), 4719-4736. https://doi.org/10.1021/acsami.8b13794